MCP
TSHA icon

Militia Capital Partners’s Taysha Gene Therapies TSHA Stock Holding History

Militia Capital Partners’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$256K Sell
46,500
-20,300
-30% -$98.6K 0.1% 165
2025
Q3 		$218K Hold
66,800
– – 0.1% 159
2025
Q2 		$154K Buy
+66,800
New +$145K 0.07% 157

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Militia Capital Partners's TSHA Position: Q4 2025 in Review

Militia Capital Partners reduced its Taysha Gene Therapies (TSHA) stake by 30% in Q4 2025, selling an estimated $98.6K and leaving 46,500 shares worth $256K. The position accounts for 0.1% of the portfolio, ranked #165.

Militia Capital Partners first reported a position in TSHA in Q2 2025 and has held it in 3 quarters since. 195 funds tracked by Wall St. Rank hold TSHA as of Q4 2025.

  • Militia Capital Partners held 46,500 shares of Taysha Gene Therapies worth $256K as of Q4 2025.
  • Militia Capital Partners sold 20,300 Taysha Gene Therapies shares in Q4 2025, an estimated $98.6K.
  • Taysha Gene Therapies made up 0.1% of Militia Capital Partners's portfolio in Q4 2025, its #165 holding.
  • Militia Capital Partners first reported a position in Taysha Gene Therapies in Q2 2025 and has held it in 3 quarters since.
  • 195 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q4 2025.

Based on Militia Capital Partners's 13F filing for Q4 2025, filed 17 Feb 2026.